149 related articles for article (PubMed ID: 27612035)
1. Should we stop offering indium-111 octreotide scans in favour of gallium-68 PET-CT scans in the UK?
Kalsy N; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1221-1222. PubMed ID: 27612035
[No Abstract] [Full Text] [Related]
2. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
[No Abstract] [Full Text] [Related]
3. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
4. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?
Öberg K
Endocrine; 2012 Aug; 42(1):3-4. PubMed ID: 22562721
[No Abstract] [Full Text] [Related]
5. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
[TBL] [Abstract][Full Text] [Related]
6. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?
Basu S; Ostwal V
Nucl Med Commun; 2016 Jun; 37(6):669-71. PubMed ID: 27105440
[No Abstract] [Full Text] [Related]
7. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP
J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438
[TBL] [Abstract][Full Text] [Related]
8. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
10. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
11. Fibromatosis mimicking relapse of a neuroendocrine tumor at 68Ga-DOTATOC positron-emission tomography/computed tomography.
Trevisi E; Facilissimo I; Taraglio S; Brizzi MP
J Cancer Res Ther; 2022; 18(4):1171-1173. PubMed ID: 36149180
[TBL] [Abstract][Full Text] [Related]
12. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
13. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
14. What will be required to bring ⁶⁸Ga-labelled peptides into routine clinical use?
Ballinger JR; Solanki KK
Nucl Med Commun; 2011 Dec; 32(12):1109-12. PubMed ID: 21934542
[No Abstract] [Full Text] [Related]
15. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
Treglia G; Castaldi P; Rindi G; Giordano A; Rufini V
Endocrine; 2012 Aug; 42(1):80-7. PubMed ID: 22350660
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance and clinical impact of
Hou G; Cheng X; Yang Y; Zhao D; Wang G; Zhao H; Zheng R; Wang X; Chen X; Chi Y; Zhang J
Theranostics; 2024; 14(8):3213-3220. PubMed ID: 38855183
[No Abstract] [Full Text] [Related]
18. Clinical applications of Gallium-68.
Banerjee SR; Pomper MG
Appl Radiat Isot; 2013 Jun; 76():2-13. PubMed ID: 23522791
[TBL] [Abstract][Full Text] [Related]
19. Gallium-68 PET: a new frontier in receptor cancer imaging.
Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
[TBL] [Abstract][Full Text] [Related]
20. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
Smith DL; Breeman WA; Sims-Mourtada J
Appl Radiat Isot; 2013 Jun; 76():14-23. PubMed ID: 23232184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
